Skip to main content
EQRXinactive

EQRx, Inc.

Biopharma developer (SEC filing verified)·Phase 3·CEO: Massachusetts August
OncologyImmunologyDermatologyMusculoskeletal

EQRX evidence brief

What we can confirm

BioSniper Score:
8.5 / 10
Lead Asset:
aumolertinib (Phase 3)

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

BioSniper Score: 8.5 / 10 · Lead Asset: aumolertinib (Phase 3)
BioSniper AIPage context preserved

Prepared research question

What matters most for EQRX—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

8.5/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

aumolertinib (Phase 3)

Next Catalyst

—

Tracking 5 pipeline candidates for EQRx, Inc..

Run EQRx, Inc. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available EQRx, Inc. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

Cash RunwayN/A

Cash runway data unavailable

Financial HealthN/A

Financial health data unavailable

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth8.5

5 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company

Frequently asked questions

What is EQRx, Inc.'s lead drug candidate?

EQRx, Inc.'s most advanced tracked candidate is aumolertinib (Phase 3) for EGFR-mutated non-small cell lung cancer (NSCLC).

Who is the CEO of EQRx, Inc.?

Massachusetts August is the chief executive officer of EQRx, Inc. (EQRX).

What therapeutic areas does EQRx, Inc. focus on?

EQRx, Inc. develops therapies across Oncology, Immunology, Dermatology, Musculoskeletal.

923 active companies304,861 SEC filings22,725 clinical trials
Citation log window (7 days): 13,363 recorded LLM calls; 0 block events, 0 warning events. These counts do not measure factual accuracy or research quality.Computed at
How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.